e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

Core Insights - Tangram Therapeutics has relaunched as a biotech company focused on RNA interference (RNAi) medicines, aiming to accelerate the discovery and development of innovative treatments [2][6] - The company has introduced LLibra OS, a next-generation AI platform designed to enhance the identification and evaluation of gene targets and siRNA design [4][5] Company Overview - Tangram Therapeutics, formerly known as e-therapeutics, combines computational methods, RNAi technology, and proprietary chemistry to develop medicines more efficiently [2][7] - The company’s lead program, TGM-312, targets metabolic dysfunction-associated steatohepatitis (MASH) and is on track for a Clinical Trial Application (CTA) submission in Q4 2025 [3][7] - Another program, TGM-148, is focused on bleeding disorders, with a regulatory submission planned for mid-2026 [3][7] Technological Advancements - LLibra OS is built on the previous computational platform HepNet and integrates various datasets to identify novel therapeutic targets [4][5] - The platform aims to improve decision-making in the development process, thereby reducing risks and accelerating the timeline for bringing GalOmic medicines to market [5][6] Strategic Vision - The relaunch signifies a strategic shift towards a data-driven approach in RNAi medicine development, leveraging AI and proprietary chemistry to create differentiated treatment options [5][6] - The company emphasizes the importance of making non-obvious connections between diverse information to support the development of first-in-class programs [6]